Staging by computed tomography scan of the neck, chest, and upper abdomen ruled out systemic spread. Because of the patient's advanced age, frail health status, and his adamant opposition, chemotherapy was deferred. Instead, he was referred to radiation oncology for a course of regional electron beam therapy. It was believed that radiation therapy might adequately control his disease and would not present the morbidity risks involved with chemotherapy and/or a more aggressive wide excision.9 Six MeV radiation was used to deliver a 60-Gy surface dose to the ear area and 50 Gy to deep upper cervical nodes, facial nodes, and adjacent skin to the level of the larynx. The patient tolerated the 5 weeks of radiation treatment well, with mild skin erythema to the region. The patient was followed closely; at a routine follow-up in February 2003, examination revealed a new 1-cm, right-sided preauricular pearly nodule. The patient revealed that the lesion had been present for 10 days. The new lesion appeared to be outside the previously treated radiation field. Excision was done using Mohs micrographic surgery, and the pathology results revealed clusters of undifferentiated neoplastic cells, some of which appeared to be within the lymphatics. This outcome, along with the immunohistochemistry results, confirmed that the lesion was the same histologic type as the primary lesion. Shortly thereafter, the patient developed 2 new lesions on the right temple (0.8- and 1.3-cm irregular subcutaneous nodules). Pathology of these nodules also was consistent with MCC, with lymphatic and vascular involvement and positive margins of the resected area. The new lesions were then treated with a second course of electron beam therapy with a generous field that included some overlap with the previously irradiated area. Chemotherapy was again discussed with the patient, who strongly declined this option despite disease progression. His age and ability to tolerate the chemotherapeutic side effects involved were considerations in the patient's decision. In October 2003, a second course of 6 MeV radiation to the right temple and anterior right cheek over 25 treatment sessions was completed. Despite the widened field of radiation, several new nodules developed during its course. These involved the superior aspect of the right ear, right nasolabial fold, upper left temple, left preauricular regions, and posterior neck. In November 2003, a magnetic resonance image of the spine demonstrated systemic spread with bone metastasis involving the C2 and C3 vertebral bodies. A third round of radiation, now considered palliative, was directed to the cervical spine. With the patient finally concurring, a mild chemotherapeutic regimen of pamidronate and capecitabine also was planned. These treatments were discontinued after 2 courses because of failure to thrive. Bone metastases and cutaneous involvement continued to progress. Despite the unfavorable prognosis, the patient requested further treatment, and a single regimen of oral etoposide was chosen.
Comment
Treatment of a primary lesion without evidence of spread, or stage I disease, has historically been wide excision; however, acceptable margins have been debated, ranging from 1 to 3 cm. The addition of postsurgical irradiation of 50 to 60 Gy to the area of the lesion and all draining lymph node basins has been found to decrease local recurrence but has not been found to have a major impact on survival rates, given the frequency of distant metastasis in MCC.10 Mortier et al9 recently reported similar outcomes with radiation therapy alone and with wide excision followed by radiation for inoperable stage I disease. Prophylactic radiation (40–60 Gy) to the draining lymph node basin also has been proposed for stage I, though it has not been thoroughly investigated. Mohs micrographic surgery may have a significant impact on the primary treatment of MCC. Local recurrence rates with Mohs micrographic surgery are lower than with wide excision because thorough histologic evaluation of margins is best.11,12 Radiation at the primary site is indicated when clear margins cannot be achieved.12 In the case of successful excision by Mohs micrographic surgery, adjuvant radiation therapy has not been shown to lower the rates of recurrence. However, irradiation of the lesion, including the draining lymph node basin, may improve regional control and increase the disease-free interval.9 MCC spreads to regional lymph nodes within 2 years in 70% of cases.13 When lymph nodes are affected, 5-year survival is approximately 50%. Historically, regional lymphadenectomy was used in those patients with confirmed or suspected lymph node spread. Due to the morbidity risks of this procedure, this technique has fallen out of favor.14 A newer alternative is sentinel lymph node biopsy. The usefulness of this modality for the overall impact on survival is debated.6 Given the morphologic and immunohistologic similarities to small cell carcinoma, MCC also is similarly chemosensitive. Although there is no doubt about the efficacy of adjuvant chemotherapy in vitro, its benefit in preventing recurrence is debated. It is most widely accepted as a last-line effort in stage II disease to prevent progression to distant metastasis, and in stage III disease as a palliative effort.15 In the limited studies of chemotherapy for cases of MCC, the response rate to first-line therapy approached only 65%. Dose-response figures have not been established.11 In the investigation into the use of chemotherapy as a first-line therapy, chemotherapy regimens employed in small cell lung carcinoma (cyclophosamide, doxorubicin, vincristine, or etoposide-cisplatin) may provide a useful guide. Although combinations such as cisplatin-doxorubicin are acceptable in patients younger than 65 years, elderly patients are often poor candidates given their comorbidities. Some monotherapy regimens, such as oral etoposide, have been successful.10 Risks, including neutropenia and peripheral neuropathy, are magnified by the pharmacodynamic changes in absorption and metabolism that occur with age. Human growth factors such as granulocyte colony-stimulating factor, macrophage-macrophage colony-stimulating factor, and recombinant human erythropoietin have been supplemented in more elderly patients in an attempt to reduce morbidity and increase dose escalations.11 The lack of data on chemotherapy in the elderly population is not unique to MCC; rather, it is a common problem in cancer research. Most cancers occur in patients 65 years and older, yet there is a paucity of data on the effects of chemotherapy because elderly patients are poor candidates for phase 1 and phase 2 trials. Therefore, existing knowledge of the pharmacophysiology of aging must be used to extrapolate the most appropriate dosing and drug combinations. New treatment modalities are being explored. Immunotherapy has shown some results for early stage MCC. Interferon alfa 2b and tumor necrosis factor have shown some promise. The antigens mucin 1 and epithelial cell adhesion molecule are expressed in 85% and 70% of MCC cases, respectively.16 Current research is directed at developing antibodies to these antigens. Somatostatin receptor scintigraphy along with sentinel lymph node biopsy might become another tool with which to detect micrometastasis. Reverse transcription polymerase chain reaction can be used to find markers such as cytokeratin 20 on MCC cells circulating in the peripheral blood pool.17 This would allow identification of patients at high risk for systemic spread and relapse. To date, no treatment has been found to successfully arrest distant metastases.
Conclusion